Highmark GLP-1 Coverage & Prior-Authorization Guide (2026)

Highmark serves members across Delaware, New York, Pennsylvania, and West Virginia, and it publishes its GLP-1 anti-obesity prior-authorization criteria through named policy bulletins rather than a single master document. We pulled the current pharmacy policy bulletins directly from Highmark's public pharmacy-policy portal — J-1388 Anti-Obesity (Enhanced), version 028, effective 07/01/2026, and J-1389 Anti-Obesity (Standard), version 013, effective 04/24/2026 — along with the 2024 Special Bulletin and provider-manual appeal rules. If your Highmark prior authorization for Wegovy, Saxenda, Zepbound, or Foundayo has been delayed or denied, this is the source-of-truth for every clause your prescriber can address — starting with the question most members never get answered: which of the two policies your plan elected.

The bottom line

• Highmark covers Wegovy (injection and oral tablet), Saxenda, Zepbound, and Foundayo (orforglipron) for chronic weight management only when the member's specific plan includes an anti-obesity pharmacy benefit, and only through strict prior authorization.
• There are two very different rulebooks. The Enhanced policy (J-1388) — the one applied to fully-insured and ACA plans since late 2024 — requires baseline BMI ≥ 40 plus a metabolic or organ-dysfunction requirement, step therapy through plan-preferred Zepbound, and a ≥ 7.5% weight-loss reauthorization gate. The Standard policy (J-1389), which self-insured employer groups can elect instead, is far more permissive: BMI ≥ 30 (or ≥ 27 with one weight-related comorbidity), a 3-month lifestyle-program attestation, no type-2-diabetes exclusion, no Zepbound step therapy, and a ≥ 5% continuation gate.
• Diabetes GLP-1s — Ozempic and Mounjaro — are unaffected and remain covered under separate diabetes criteria.
• Many self-insured employer groups (ASO) exclude the anti-obesity benefit entirely, so a member can fail every clinical criterion check and still have no path to coverage because the benefit itself was never purchased by their employer.

What Highmark actually covers

The single biggest source of confusion in Highmark GLP-1 denials is not the clinical criteria — it's whether the anti-obesity pharmacy benefit exists on the member's plan at all. Highmark draws a hard line between two plan types, and the criteria below only apply to one of them.

• Fully-insured and ACA plans are subject to Highmark's revised anti-obesity policy. New-to-therapy members in Delaware and West Virginia moved to the tightened criteria 09/01/2024; New York also moved 09/01/2024; Pennsylvania moved 10/01/2024. Members with an existing prior authorization transition to the new criteria at reauthorization, after an advance notice letter (60 days in PA/DE/WV; 90 days in NY, following 2025 group renewal).
• Self-insured (ASO / employer-group) plans are not automatically impacted. Prior-authorization criteria for weight-loss medications on Highmark's commercial self-insured book were unchanged by the 2024 revision, and the anti-obesity benefit itself is optional per employer group — each ASO group separately elects the “Enhanced” policy (J-1388), the “Standard” policy (J-1389), or excludes the anti-obesity benefit entirely. J-1388 itself covers Commercial and Healthcare Reform (ACA) lines of business; J-1389 is Commercial-only.
• Zepbound is the plan-preferred GLP-1 under the Enhanced policy only. Under J-1388, Foundayo, Saxenda, and Wegovy require documented therapeutic intolerance (severe side effects not resolved by diet modification or dose de-escalation) or a contraindication to Zepbound first. The Standard policy (J-1389) has no Zepbound step — its only step-therapy rule is generic liraglutide before brand Saxenda.
• Diabetes GLP-1s are carved out. Ozempic and Mounjaro, prescribed for type 2 diabetes, are governed by separate diabetes criteria and are not affected by any of the anti-obesity restrictions described here.
• Current governing policy versions for new users are J-1388-028 Anti-Obesity (Enhanced), effective 07/01/2026, and J-1389-013 Anti-Obesity (Standard), effective 04/24/2026 — both published as public PDFs on Highmark's pharmacy-policy portal (linked in the references). Policy J-0184 is a transition policy that applies only to established users until their existing prior authorization expires (in New York, until the plan renews) — after which J-1388 or J-1389 applies.
• Foundayo (orforglipron) and the Wegovy oral tablet are now formal target agents in both policies — in effect in J-1389-013 (effective 04/24/2026) and J-1388-028 (effective 07/01/2026). This supersedes the January 2026 “effective upon internal review” announcement.

Prior authorization criteria (Enhanced policy J-1388)

The Enhanced policy (J-1388-028, effective 07/01/2026) governs Foundayo, Saxenda, Wegovy (injection and oral tablet), and Zepbound for fully-insured and ACA members whose plan carries the anti-obesity pharmacy benefit — and for self-insured groups that elected Enhanced. Full adult criteria:

• Applies only to members whose plan includes the anti-obesity pharmacy benefit; Zepbound is plan-preferred — Foundayo, Saxenda, and Wegovy require documented therapeutic intolerance or contraindication to Zepbound first (step therapy), and brand Saxenda additionally requires failure or intolerance to generic liraglutide.
• Age ≥ 18 (separate adolescent criteria apply for ages 12–17); use for chronic weight management, ICD-10 E66.0 or E66.3.
• Baseline BMI ≥ 40 kg/m² PLUS one of: (A) prediabetes (A1C 5.7–6.4%, fasting plasma glucose 100–125, or OGTT 140–199) AND triglycerides ≥ 150 mg/dL AND HDL < 40 (men) / < 50 (women); OR (B) one severe obesity-caused organ-dysfunction manifestation (coronary artery disease, MASH with F2–F3 fibrosis, myocardial infarction, stroke, peripheral arterial or vascular disease, or moderate-to-severe obstructive sleep apnea); OR (C) at least two manifestations from a broader list (e.g. severe knee or hip pain with reduced range of motion, hypertension or another qualifying cardiovascular disease, PCOS, male hypogonadism, chronic urinary incontinence, significant mobility limitations).
• Documentation of healthy dietary changes AND increased physical activity for at least 6 months prior to initiation, continued during therapy — with one piece of acceptable documentation from each column of the policy's Table A (chart notes, recurring gym or lifestyle-program receipts, wearable summaries, dietary logs, or nutrition-counseling appointments).
• Prescriber must attest the member does NOT have a type 2 diabetes diagnosis.
• The drug must not be used in combination with any other GLP-1 receptor agonist or GLP-1/GIP combination product.

Reauthorization and adolescent criteria:

1. Reauthorization / maintenance (≥ 7 months on therapy): documented and maintained ≥ 7.5% weight loss from baseline plus maintenance dosing (Wegovy injection 1.7/2.4/7.2 mg weekly; Wegovy oral tablet 25 mg daily; Zepbound 5/7.5/10/12.5/15 mg weekly; Saxenda 2.4/3 mg daily; Foundayo 5.5/9/14.5/17.5 mg daily). Non-GLP-1 oral agents (Contrave, Qsymia, Xenical) use a lower baseline BMI ≥ 35 with a ≥ 5% reauthorization threshold instead.
2. Adolescent Saxenda/Wegovy: baseline BMI ≥ 35 kg/m² or ≥ 120% of the 95th percentile for age and sex; maintenance requires a maintained ≥ 5% BMI reduction from baseline.

Prior authorization criteria (Standard policy J-1389)

The Standard policy (J-1389-013, effective 04/24/2026, Commercial line of business only) is the alternative anti-obesity rulebook a self-insured employer group can elect instead of Enhanced — and it is dramatically more permissive. If your employer plan elected Standard, the BMI-40 wall, the type-2-diabetes exclusion, and the Zepbound step described above do not apply to you. Full adult GLP-1 initiation criteria (Saxenda, Foundayo, Wegovy, Zepbound):

• Age ≥ 18; use for chronic weight management, ICD-10 E66.0 or E66.3.
• Prescriber attestation of baseline height, weight, and BMI, with baseline BMI ≥ 30 kg/m² — or BMI ≥ 27 kg/m² with one weight-related comorbidity (the policy's own examples: hypertension, cardiovascular disease, dyslipidemia, obstructive sleep apnea).
• Prescriber attestation that the member actively participated in a lifestyle modification program for at least 3 months before starting therapy and will continue it during therapy — attestation only, versus Enhanced's 6 months of receipts-level documentation.
• No combination use with another GLP-1 receptor agonist or GLP-1 combination product.
• If the request is for brand Saxenda: therapeutic failure or intolerance to plan-preferred generic liraglutide first. That is the Standard policy's only step-therapy rule — there is no Zepbound-preferred step.
• No type-2-diabetes attestation. Unlike Enhanced, Standard does not require the prescriber to attest the member is free of a T2D diagnosis.

Continuation and maintenance under Standard: through month 12, the member must have achieved ≥ 5% weight loss from baseline (Saxenda: ≥ 4%) plus maintenance dosing (Wegovy injection 1.7/2.4/7.2 mg weekly; Wegovy oral 25 mg daily; Zepbound 5–15 mg weekly; Foundayo 5.5/9/14.5/17.5 mg daily). Beyond 12 months, the member must have maintained that ≥ 5% (Saxenda ≥ 4%) loss. Initiation approvals run 4–7 months depending on the drug (Saxenda 4, Wegovy 6, Foundayo and Zepbound 7); continuation and maintenance approvals are 12 months each.

Verbatim policy language

Highmark's own Special Bulletin language on the four points most prescribers get wrong:

“For Saxenda, Wegovy, and Zepbound for initiation and maintenance in adults, requiring age of 18 years or older, use for chronic weight management, baseline BMI ≥ 40 kg/m2, at least two weight-related comorbidities … attestation that the member does not have type 2 diabetes, that the agent will not be used with any other GLP-1 RA containing agent, and if the request is for Saxenda or Wegovy, intolerance/contraindication to plan-preferred Zepbound. Additionally for maintenance, weight loss of ≥ 7.5% from baseline and maintenance dosing.”

— Highmark Special Bulletin (Aug 30, 2024) — Revised Prescription Medication Policy for Weight Loss Medications; Anti-Obesity Fully-Insured Commercial & ACA policy, eff. 09/01/2024

“Prior authorization criteria for weight loss medications for Highmark's commercial self-insured members is not impacted.”

— Highmark Special Bulletin (Aug 30, 2024) — Revised Prescription Medication Policy for Weight Loss Medications

“This policy change also does not affect FDA-approved GLP-1s used in the treatment of type 2 diabetes.”

— Highmark Special Bulletin (Aug 30, 2024) — Revised Prescription Medication Policy for Weight Loss Medications

“i. The member has a baseline BMI ≥ 30 kg/m² ii. The member has a baseline BMI ≥ 27 kg/m² and has a weight related comorbidity (for example hypertension, cardiovascular disease, dyslipidemia, obstructive sleep apnea).”

— Highmark Pharmacy Policy Bulletin J-1389-013, Anti-Obesity (Standard) — Commercial, Approval Criteria §V.A.3.b, eff. 04/24/2026

“A provider has 180 days from the date of the initial denial of coverage in which to file an appeal in all of Highmark's service areas in Delaware, New York, Pennsylvania, and West Virginia.”

— Highmark Provider Manual, Chapter 5 Unit 5: Denials, Adverse Benefit Determinations, Grievances, and Appeals

How to appeal a denial

Members or the treating provider may appeal an adverse determination within 180 days of the initial denial, across all four Highmark service areas (Delaware, New York, Pennsylvania, and West Virginia). A grievance may likewise be filed up to 180 days after the original determination, and appeals can be filed by telephone or in writing.

1. Request the written denial letter that names the specific policy clause (J-1388, J-1389, or the J-0184 transition policy) your submission failed to satisfy.
2. For commercial members, Highmark also offers a physician peer-to-peer review before or at the point of denial — use it to resolve documentation gaps before filing a formal appeal.
3. File the internal appeal within 180 days, addressing the specific clause named in the denial letter (BMI threshold, comorbidity documentation, the diet/activity record, the type-2-diabetes attestation, or the reauthorization weight-loss calculation — ≥ 7.5% under Enhanced, ≥ 5% under Standard). If the denial applied Enhanced criteria (BMI ≥ 40, Zepbound step) to a plan that elected the Standard policy, appeal on that basis first.
4. Pennsylvania CHIP/Healthy Kids members have a shorter 60-day appeal window — do not assume the standard 180-day window applies.
5. If the internal appeal is denied, members may request an external independent review. Call the Member Service number on the ID card, or follow the appeal instructions printed in the denial letter.

Further reading

• Aetna GLP-1 prior authorization guide — how a different national payer structures its PA bulletins by drug.
• Best semaglutide providers — vetted cash-pay telehealth options if your Highmark plan excludes the anti-obesity benefit.
• Best tirzepatide providers — cash-pay options for members whose plan requires a Zepbound step they can't clear.